DJIA 17,630.27 189.68 1.09%
NASDAQ 5,089.21 49.43 0.98%
S&P 500 2,093.25 25.61 1.24%
market minute promo

28.89 0.39 (1.37%)

Quote as of

Extended Hours: $28.89 $0.00 (0.00%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

XLRN $28.89 1.37%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $28.77
Previous Close $28.50
Daily Range $27.76 - $29.61
52-Week Range $23.61 - $48.50
Market Cap $947.9M
P/E Ratio -16.01
Dividend (Yield) $0.00 (0.0%)
Volume 119,729
Average Daily Volume 170,462
Current FY EPS -$1.34

Sector

Industry

CONTROLADORA VUELA SPON ADR REPR 10 CPOS (XLRN) Description

CONTROLADORA VUELA SPON ADR REPR 10 CPOS Website: http://www.acceleronpharma.com/

News & Commentary Rss Feed

Stocks To Watch in Orphan Drugs

Acceleron Pharma, bluebird bio, and Sarepta Therapeutics are three rare disease specialists with upcoming catalysts that could propel their shares higher.

XLF, UBIO: Big ETF Inflows

Acceleron Pharma Has 2 Drug Candidates That Could Become Blockbusters

Notable ETF Outflow Detected - BIB, ACAD, XLRN, ACRX

Celgene Rapid Growth Is Still Ahead For 2016 Through 2020

Multiple Observations On Celgene's Latest Licensing Deals, And Its Valuation

Acceleron Reports Publication in Cancer Research Dalantercept Prevents Metastases in Preclinical Stu

Acceleron Reports Publication in Cancer Research Dalantercept Prevents Metastases in Preclinical Studies of Breast Cancer

Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European H

Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology Association

These 3 Ultra-Rare Diseases Are Utterly Terrifying

Despite three decades of intense work leading to over 400 new treatments, we have barely made a dent in the vast unmet medical need for rare diseases. Here is a look at three striking examples underscoring the point.

The Zacks Analyst Blog Highlights: Eleven Biotherapeutics, bluebird, Agios, Acceleron and Achillion

The Zacks Analyst Blog Highlights: Eleven Biotherapeutics, bluebird, Agios, Acceleron and Achillion - Press Releases

See More XLRN News...